Objective Enhanced recovery after surgery (ERAS) has been successfully adopted for the improvement of medical quality and efficacy in many diseases, but the effect thereof for ankle fracture patients can vary. The aim of the present study was to explore the short‐term postoperative outcomes of ERAS among ankle fracture patients. Methods The present study was a retrospective cohort study conducted between January 2019 and May 2019. One hundred and sixty ankle fracture participations (58 males and 102 females, aged 41.71 ± 14.51 years) were included. The participants treated with open reduction and internal fixation were divided into two groups (non‐ERAS vs. ERAS) depending on whether ERAS was applied. Postoperative outcomes included American Orthopedic Foot and Ankle Society (AOFAS) score, length of stay (LOS), hospital cost, complications, and consumption of opioids. To assess the association between the groups and outcomes, generalized estimating equation (GEE) modeling and multivariable linear regression analysis were performed. Results The average follow‐up periods of the participations were 24 months postoperatively. No significant differences were detected between the non‐ERAS group and ERAS group with respect to the demographic of patients in terms of gender, age, Danis‐Weber classification of fracture, dislocation of ankle joint, and comorbidity (P > 0.05). Significant differences in terms of a higher AOFAS score were found in the ERAS group compared with the non‐ERAS group (6.73, 95% CI, 5.10–8.37, p < 0.001) at 3 months postoperatively (PO3M) and (4.73, 95% CI, 3.02–6.45, p < 0.001) at 6 months postoperatively (PO6M). However, similar AOFAS scores were found at 12 months postoperatively (PO12M) (0.28, 95% CI, −0.32 to 0.89, P > 0.05) and at 24 months postoperatively (PO24M) (0.56, 95% CI, −0.07 to 1.19, P > 0.05). Additionally, the GEE analysis and group‐by‐time interaction of AOFAS score revealed that the ERAS protocol could facilitate faster recovery for ankle fracture patients, with higher PO3M and PO6M (both P < 0.05). At the same time, significant differences in terms of a shorter length of stay (−3.19, 95% CI, −4.33 to −2.04, P < 0.01) and less hospital cost (−6501.81, 95% CI, −10955.21 to −2048.42, P < 0.01) were found in the ERAS group compared with the non‐ERAS group. Conclusion By reducing LOS and hospital cost, the ERAS protocol might improve the medical quality and efficacy. The present study can provide a realistic evaluation and comparison of the ERAS protocol among ankle fracture patients, and ultimately guide clinical decision making.

In recent years, an increasing number of studies have reported that long non-coding RNAs (lncRNAs) play essential regulatory roles in myogenic differentiation. In this study, a specific LncRNA XLOC_015548 (Lnc000280) was identified. However, little research has explored its mechanism of action by constructing XLOC_015548 gene editing cell models. In this study, relevant sequences were obtained according to the RNA-seq results. Subsequently, XLOC_015548 knockdown and over-expression lentiviral vectors were constructed, and the C2C12 myoblast cell line was transfected to prepare the XLOC_015548 gene-edited myoblast model. The in vitro analysis revealed that over-expression of XLOC_015548 significantly promoted the proliferation and differentiation of myoblasts and the formation of myotubes, whereas the opposite result was obtained in the knockdown group. XLOC_015548 regulated myogenic differentiation and affected the expression of myogenic differentiation regulators such as Myod, myogenin, and MyHC. Regarding the signaling pathway, we found that XLOC_015548 correlated with the phosphorylation level of MAPK/MEK/ERK pathway proteins. And the degree of phosphorylation was positively correlated with the protein expression of myogenic differentiation regulators. In conclusion, a new gene-edited myoblast model was constructed based on the lncRNA regulator XLOC_015548. The in vitro cell experiments verified that XLOC_015548 had regulatory effects on muscle growth and myoblast differentiation. These findings provide a laboratory foundation for the clinical application of lncRNAs as regulatory factors in the treatment of disuse muscle atrophy.

Review question / Objective: For the sake of better apprehending the nexus between ferroptosis and chondrocytes in osteoarthritis (OA), proffering novel insights and opening-up new orientation for in-depth research in both pre-clinical and clinical settings, it is warranted to initiate one rigorous and robust systematic review (SR) based upon up-to-date in-vivo and in-vitro research advances on this topic. To the best our knowledge, no SRs concerning ferroptosis and chondrocytes in OA have been published thus far. Condition being studied: Osteoarthritis (OA) is the most common form of arthritis, which menaces 7% of the human population globally. With the aged tendency of population and higher rates of obesity, the incidence of OA is anticipated to proliferate, which will entail a mounting impact and major challenges for global health care and each country’s public health systems unavoidably. In virtue of the onset of OA is mighty knotty, its etiology and underlying molecular mechanisms have not been expressly expounded. However, the salient role that cartilage degeneration acts in the progression of OA has been widely acknowledged. Chondrocytes are consequential for the safeguard of cartilage homeostasis and the functional integrity of the articular cartilage. Once the homeostatic equilibrium of the extracellular matrix (ECM) synthesis and degradation is smashed, OA comes up.

Background: Enhanced recovery after surgery (ERAS) has been successfully adopted for the improvement of medical quality and efficacy in many diseases but the effect among the ankle fracture patients is variable. We intended to explore the short-term outcomes of ERAS among ankle fracture patients.Methods: One hundred sixty ankle fracture participations (41.71 ± 14.51 years-old) grouped into two groups (non-ERAS Vs. ERAS) with an average of 24 months follow-up were included in the retrospective study. Multivariable linear regression analysis and generalized estimating equation (GEE) model were performed to assess the association of outcomes including American Orthopaedic Foot and Ankle Society (AOFAS), length of stay (LOS), and hospital cost.Results: Analysis revealed that the patients in the ERAS group could obtain higher AOFAS score with LOS or hospital cost reduction than that in the ERAS group (p＜0.05) at month 3 postoperatively (PO3M) and month 6 postoperatively (PO6M). However, outcomes were comparable at month 12 postoperatively (PO12M) and later.GEE analysis and group by time interaction of AOFAS revealed the ERAS protocol could help ankle fracture patients recover faster and better in the short-term.Conclusions: Ankle fracture patients could recover better with the application of the ERAS protocol, especially in the short-term periods, all patients would obtain comparable function PO12M later. The ERAS protocol might improve medical quality and efficacy by reducing LOS and hospital costs as well. The current study would provide a realistic evaluation and comparison of the ERAS protocol among the ankle fracture patients for the surgeons in the short-term.